Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TSC 201

Next Previous
Drug Profile

TSC 201

Alternative Names: TSC-201

Latest Information Update: 26 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TScan Therapeutics
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Anal cancer; Head and neck cancer; Macroglobulinaemia; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 25 Apr 2024 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Combination therapy) in USA (Parenteral) (TScan Therapeutics pipeline, April 2024) (NCT05973487)
  • 25 Apr 2024 Phase-I clinical trials in Solid tumours (Monotherapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (Parenteral) (TScan Therapeutics pipeline, April 2024) (NCT05973487)
  • 06 Mar 2024 Tscan Therapeutics plans a phase I trial for Solid tumours in the first quarter of 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top